Oruka Therapeutics (NASDAQ:ORKA) CEO Lawrence Otto Klein Sells 1,729 Shares of Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) CEO Lawrence Otto Klein sold 1,729 shares of Oruka Therapeutics stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $69.69, for a total value of $120,494.01. Following the completion of the transaction, the chief executive officer owned 925,580 shares in the company, valued at approximately $64,503,670.20. This represents a 0.19% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Oruka Therapeutics Stock Down 1.5%

Oruka Therapeutics stock opened at $68.86 on Tuesday. Oruka Therapeutics, Inc. has a 12-month low of $10.77 and a 12-month high of $91.00. The business’s 50-day moving average price is $63.71 and its two-hundred day moving average price is $44.31. The stock has a market cap of $4.15 billion, a PE ratio of -35.49 and a beta of -0.25.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.04. As a group, analysts expect that Oruka Therapeutics, Inc. will post -2.06 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. Leerink Partners set a $120.00 price target on Oruka Therapeutics in a report on Thursday, April 30th. Barclays boosted their price target on Oruka Therapeutics from $78.00 to $160.00 and gave the stock an “overweight” rating in a report on Monday, April 27th. BTIG Research restated a “buy” rating and set a $151.00 price target on shares of Oruka Therapeutics in a report on Thursday, May 14th. UBS Group boosted their price target on Oruka Therapeutics from $75.00 to $100.00 and gave the stock a “buy” rating in a report on Tuesday, April 28th. Finally, Wall Street Zen cut Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $131.30.

Hedge Funds Weigh In On Oruka Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Royal Bank of Canada lifted its stake in shares of Oruka Therapeutics by 47.2% in the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after acquiring an additional 365 shares during the period. Los Angeles Capital Management LLC acquired a new position in shares of Oruka Therapeutics in the fourth quarter worth approximately $37,000. PNC Financial Services Group Inc. acquired a new position in shares of Oruka Therapeutics in the third quarter worth approximately $39,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Oruka Therapeutics in the fourth quarter worth approximately $67,000. Finally, Russell Investments Group Ltd. acquired a new position in shares of Oruka Therapeutics in the third quarter worth approximately $43,000. 56.44% of the stock is owned by institutional investors and hedge funds.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on the development of novel peptide?based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell?permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.